Clinical course and prognosis of patients with chronic obstructive pulmonary disease.
Clinical course and prognosis of patients with chronic obstructive pulmonary disease.
复制标题
DOI：
10.1097/00063198-200003000-00008
复制
发表时间：
2000-03-01
影响因子：
3.3
通讯作者：
Tsukino, M
中科院分区：
文献类型：
--
作者：
Nishimura, K;Tsukino, M
慢性阻塞性肺疾病（COPD）基本上是一种良性疾病，但预后很差，死亡率与某些恶性疾病相似。根据疾病的严重程度，慢性阻塞性肺病患者的5年死亡率从40%到70%不等。已确定的三大死亡原因是慢性阻塞性肺病本身、肺癌和心血管疾病。以下因素与生存相关：FEV1（特别是最大可达到的肺功能）、年龄、性别、PaO2、PaCO2、体重和合并症。已经有几项大规模随机临床试验来检验吸入抗胆碱能药物和吸入皮质类固醇对每年FEV1下降的预防作用。然而，不幸的是，在所有已发表的研究中，这些药物对FEV1的年度下降没有影响。
Chronic obstructive pulmonary disease (COPD) is a basically benign disease, but the prognosis is so poor that the mortality rate is similar to some malignant diseases. Depending on the disease severity, the 5-year mortality rate of patients with COPD varies from 40 to 70%. The three major causes of death have been identified as COPD itself, lung cancer, and cardiovascular disease. The following factors have been reported to be related to survival: FEV1 (especially the maximal attainable lung function), age, gender, PaO2, PaCO2, body weight, and comorbidity. There have been several large-scale randomized clinical trials to examine the prophylactic effects of inhaled anti-cholinergics and inhaled corticosteroids on the annual decline in FEV1. However, unfortunately, in all of the published studies, these drugs had no effect on the annual decline in FEV1.